

Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results for the Six Months Ended September 30, 2024 [Under Japanese GAAP]

November 7, 2024
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL (03) 6374-9704

Scheduled date to file semi-annual securities report: November 13, 2024

Scheduled date to commence dividend payments: December 3, 2024

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes (for investment analysts and institutional investors)

(Amounts rounded down to the nearest million yen)

1. Consolidated financial results for the six months ended September 30, 2024 (from April 1, 2024 to September 30, 2024)

(1) Consolidated operating results (cumulative)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended September 30, 2024	55,139	0.4	1,549	16.0	2,050	29.9	1,255	-33.6
September 30, 2023	54,937	11.9	1,335	—	1,578	—	1,890	—

(Note) Comprehensive income: For the six months ended September 30, 2024: 1,152 million yen (-52.8%),
For the six months ended September 30, 2023: 2,442 million yen (—%)

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended September 30, 2024	21.86	—
September 30, 2023	32.97	—

(Note) Beginning this fiscal year, the company changed accounting policies. The results of the six months ended September 30, 2023 are presented after retroactive adjustment. The year-on-year changes are not provide presented, as retrospective adjustments have been made due to changes in accounting policies.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of September 30, 2024	178,865	130,027	72.7
March 31, 2024	177,627	130,735	73.6

(Note) Equity: For the six months ended September 30, 2024: 130,027 million yen,
For the fiscal year ended March 31, 2024: 130,735 million yen

(Note) Beginning this fiscal year, the company changed accounting policies. The results for fiscal year ended March 31, 2024 are presented after retroactive adjustment.

2. Dividends

(Record date)	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2024	—	20.00	—	32.00	52.00
Fiscal year ended March 31, 2025	—	20.00			
Fiscal year ending March 31, 2025 (Forecast)			—	32.00	52.00

(Note) Revisions to the dividend forecast in the current quarter: None

3. Forecast of consolidated for the year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	123,400	3.2	6,500	4.3	6,900	1.1	5,000	−8.7	87.03

(Note) Revisions to the dividend forecast in the current quarter: None

(Note) The year-on-year change rate is presented based on a comparison with the retrospectively adjusted figures of the previous period, following retrospective adjustments due to changes in accounting policies

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None

Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other than (i) : Yes

(iii) Changes in accounting estimates : None

(iv) Restatements : None

(4) Number of shares issued (common stock)

(i) Number of issued shares at the end of the period (including treasury shares)

As of September 30, 2024: 64,607,936 shares,

Fiscal year ended March 31 2024: 64,607,936 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2024: 7,159,000 shares,

Fiscal year ended March 31 2024: 7,159,151 shares

(iii) Averaged number of shares of during the period

As of September 30, 2024: 57,448,812 shares,

As of September 30, 2023: 57,329,937 shares

* This financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

The Company plans to hold the financial results briefing for investment analysts and institutional investors on Friday, November 8, 2024. Presentation materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.